Dental Extraction in Factor XI Deficiency — Including Severe Deficiency
Clinical Scenario
Patients with Factor XI (FXI) deficiency — including those with severe deficiency — who require dental extraction present a specific hemostatic challenge. The degree of bleeding risk does not correlate simply with FXI level, making tailored, evidence-based management essential for this population.
Key Consideration
Some procedures, particularly dental extractions, can be managed without the use of blood products even in patients with severe deficiency. This has important implications for how the procedure is approached and what interventions are selected.
Treatment Approach (Partial)
The evidence-based approach involves targeted local hemostatic strategies. Antifibrinolytic therapy has been studied in this setting, as has the use of locally applied fibrin-based preparations — enabling management without blood product replacement in appropriately selected patients.
Full protocol details — including timing, sequencing, and patient selection criteria — are in the structured regimen.
References
- Some procedures, particularly dental extractions, can be managed without the use of blood products even in patients with severe deficiency.
- Studies have demonstrated that antifibrinolytic drugs alone are sufficient to cover dental extractions in patients with severe FXI deficiency.
- Nineteen patients with FXI levels of less than 14 U/dL were given oral tranexamic acid starting 12 hours before surgery and continuing for 7 days afterwards.
- A group from Israel has published data on the successful use of fibrin glue in 80 patients with congenital bleeding disorders undergoing 135 dental extractions without blood product replacement; seventeen extractions were performed in 13 patients with FXI deficiency.
- The glue (Beriplast®, Centeon) is applied through a pair of syringes, one containing calcium and thrombin, the other containing fibrinogen, FXIII, and aprotinin.
View source ↗